Drugs /

omacetaxine mepesuccinate

Back to Drugs List

Overview

Generic Name(s):
omacetaxine mepesuccinate
Trade Name(s):
Synribo
NCI Definition [1]:
A semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine mepesuccinate binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types.

Clinical Trials

View Clinical Trials for omacetaxine mepesuccinate

Omacetaxine mepesuccinate has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating omacetaxine mepesuccinate, 1 is phase 2 (0 open).

CBFB-MYH11 Fusion, KMT2A Fusion, and KMT2A-AFF1 Fusion are the most frequent biomarker inclusion criteria for omacetaxine mepesuccinate clinical trials.

Acute myeloid leukemia is the most common disease being investigated in omacetaxine mepesuccinate clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Omacetaxine Mepesuccinate
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating omacetaxine mepesuccinate and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Synribo, cgx-635, 141633, omacetaxine mepesuccinate, homoharringtonine, cephalotaxus alkaloid, hht, omacetaxine mepesuccinate (substance), 26833-87-4, 19125, omacetaxine mepesuccinate, cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), [3(r)]- (9ci), cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), [3(r)]- (9ci), 1-[(1s,3ar,14bs)-2-methoxy-1,5,6,8,9,14b-hexahydro-4h- cyclopenta[a][1,3]dioxolo[4,5-h]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2r)-2- hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), ceflatonin, omacetaxine mepesuccinate, homoharringtonine, cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), [3(r)]- (9ci), 105
NCIT ID [1]:
C1127
SNOMED ID [1]:
C-10182

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.